13F Holdings
中文EN

PHIO Phio Pharmaceuticals Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1533040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-84.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-159.0%
ROA-128.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$4.62M$3.64M$6.33M$7.01M$8.89M
SG&A expense$4.60M$3.74M$4.37M$4.45M$4.62M
Operating income-$9.22M-$7.39M-$10.82M-$11.46M-$13.51M
Pretax income———-$11.48M-$13.29M
Income tax$0$0$0$0$0
Net income-$8.70M-$7.15M-$10.83M-$11.48M-$13.29M
EBITDA-$9.22M-$7.38M-$10.77M-$11.39M-$13.44M
EPS (basic)-1.45-9.08-46.76-10.10-12.43
EPS (diluted)—-9.08-46.76-10.10-12.43
Weighted avg. shares (diluted)—787,466231,5081.14M1.07M
Banking
Net interest income—$231,000-$8,000——
Balance sheet
Cash & equivalents$21.03M$5.38M$8.49M$11.83M$24.11M
Current assets$21.48M$5.74M$9.32M$12.45M$24.73M
PP&E, net$11,000$2,000$6,000$183,000$133,000
Total assets$21.49M$5.74M$9.36M$12.81M$25.17M
Current liabilities—$1.01M$1.63M$1.94M$3.07M
Long-term debt————$0
Total debt————$0
Total liabilities$1.34M$1.01M$1.63M$1.97M$3.24M
Shareholders' equity$20.15M$4.72M$7.73M$10.84M$21.93M
Net debt————-$24.11M
Shares outstanding11.62M1.73M416,3681.14M1.13M
Cash flow statement
Operating cash flow-$7.98M-$7.11M-$10.75M-$12.13M-$11.86M
Capital expenditure$12,000$1,000$5,000$121,000$51,000
Free cash flow-$7.99M-$7.11M-$10.75M-$12.25M-$11.91M
Investing cash flow-$12,000$8,000-$5,000-$121,000-$51,000
Financing cash flow$23.64M$4.00M$7.41M-$26,000$21.72M
Depreciation & amortization$3,000$2,000$56,000$71,000$75,000
Stock-based compensation$481,000$147,000$303,000$414,000$480,000

Free plan shows the latest 5 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.